Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

NCT01819272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Met DR
DRUG: Met XR
DRUG: Placebo

Sponsor

Elcelyx Therapeutics, Inc.